Eli Lilly, Compounders and drug Zepbound
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
Verywell Health on MSN8d
Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance CoverageEli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down on off-brand versions. Eli Lilly announced in a press release last week ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback